Cetera Investment Advisers
URGN icon

Cetera Investment Advisers’s UroGen Pharma URGN Stock Holding History

Cetera Investment Advisers’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Sell
28,952
-144
-0.5% -$3.9K ﹤0.01% 3007
2026
Q1 		$523K Sell
29,096
-1,000
-3% -$20K ﹤0.01% 3467
2025
Q4 		$705K Sell
30,096
-2,000
-6% -$43.4K ﹤0.01% 3146
2025
Q3 		$640K Buy
32,096
+5,726
+22% +$103K ﹤0.01% 3179
2025
Q2 		$361K Buy
+26,370
New +$253K ﹤0.01% 3236

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Cetera Investment Advisers's URGN Position: Q2 2026 in Review

Cetera Investment Advisers reduced its UroGen Pharma (URGN) stake by 0.49% in Q2 2026, selling an estimated $3.9K and leaving 28,952 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

Cetera Investment Advisers first reported a position in URGN in Q2 2025 and has held it in 5 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Cetera Investment Advisers held 28,952 shares of UroGen Pharma worth $1.07M as of Q2 2026.
  • Cetera Investment Advisers sold 144 UroGen Pharma shares in Q2 2026, an estimated $3.9K.
  • UroGen Pharma made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3007 holding.
  • Cetera Investment Advisers first reported a position in UroGen Pharma in Q2 2025 and has held it in 5 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.